For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Attruby represents a true change. These innovative therapies stabilize the transthyretin protein, preventing its damaging build-up and reducing the impact of the disease